Core Points - The company, Lizhu Pharmaceutical Group Co., Ltd., ensures the authenticity, accuracy, and completeness of its Q3 2025 report, with all board members bearing legal responsibility for the information disclosed [2][3] - The Q3 report has not been audited, and there are no non-standard opinions from auditors [3][9] Financial Data - The company reported no need for retrospective adjustments or restatements of previous accounting data [3] - Non-recurring gains and losses are applicable, but the company does not classify any non-recurring items as recurring [4] - The company has repurchased a total of 15,376,845 A-shares, accounting for 1.70% of the total share capital, with a total expenditure of approximately RMB 570.23 million [6] Shareholder Information - The report includes details on the top ten shareholders as of September 30, 2025, but does not specify any changes in shareholding due to securities lending [5] Corporate Governance Changes - The company has decided to abolish the supervisory board and transfer its responsibilities to the audit committee of the board, in compliance with updated regulations [9][10] - Amendments to the company's articles of association have been proposed to enhance governance and operational standards [10]
丽珠医药集团股份有限公司2025年第三季度报告